Sofinnova Investments, Inc.
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 14, 2025), Sofinnova Investments, Inc. reported 60 stock positions worth $1.4 billion. Its top holding was Natera (NTRA) at 18.0% of the portfolio, followed by Vera Therapeutics (VERA, 8.7%) and Gilead Sciences (GILD, 5.2%). Compared with Q3 2024, it opened 17 new positions, sold out of 13, added to 12 and reduced 20. The biggest buy was a new position in Gilead Sciences (GILD) and the biggest sale an exit from Novo-Nordisk A/S-Spons ADR (NVO).
- Most Recent 13F
- Q2 2026
- Location
- Menlo Park, CA
- CIK
- 0001631134
- Portfolio Value
- $1.4B (Q4 2024)
- SEC Filing
- 0001104659-25-013863 ↗ filed Feb 14, 2025
Holdings Value
Holdings 60 stocks · $1.4B
| NTRA Natera Inc. | 17.99% | 1,550,280 | $245.4M | No change |
| VERA Vera Therapeutics Inc. | 8.66% | 2,793,987 | $118.2M | No change |
| GILD Gilead Sciences Inc. | 5.24% | 774,227 | $71.5M | New |
| ABBV Abbvie Inc. | 4.68% | 359,393 | $63.9M | New |
| JAZZ Jazz Pharmaceuticals PLC | 4.55% | 504,193 | $62.1M | Add +167.4% |
| SRPT Sarepta Therapeutics Inc. | 3.82% | 428,771 | $52.1M | New |
| AVBP Arrivent Biopharma Inc. | 3.31% | 1,696,752 | $45.2M | No change |
| AZN Astrazeneca PLC-Spons ADR | 3.13% | 651,344 | $42.7M | Reduce -19.5% |
| SYK Stryker Corp. | 3.06% | 116,005 | $41.8M | New |
| AXSM Axsome Therapeutics Inc. | 3.05% | 491,726 | $41.6M | Add +29.6% |
| REPL Replimune Group Inc. | 2.80% | 3,149,522 | $38.1M | Add +6442.7% |
| INCY Incyte Corp. | 2.65% | 524,267 | $36.2M | Reduce -26.6% |
| RAPP Rapport Therapeutics Inc. | 2.59% | 1,995,594 | $35.4M | No change |
| SLNO Soleno Therapeutics Inc. | 2.49% | 757,248 | $34.0M | Add +29.1% |
| BSX Boston Scientific Corp. | 2.27% | 346,571 | $31.0M | Add +155.2% |
| IDYA Ideaya Biosciences Inc. | 2.01% | 1,069,090 | $27.5M | Reduce -38.9% |
| ALNY Alnylam Pharmaceuticals Inc. | 1.90% | 110,157 | $25.9M | New |
| ALKS Alkermes PLC | 1.89% | 894,266 | $25.7M | New |
| DYN Dyne Therapeutics Inc. | 1.85% | 1,071,498 | $25.2M | Add +38.8% |
| DXCM Dexcom Inc. | 1.65% | 290,210 | $22.6M | New |
| RYTM Rhythm Pharmaceuticals Inc. | 1.63% | 397,428 | $22.2M | Add +43.6% |
| GMED Globus Medical Inc. Class A | 1.48% | 244,700 | $20.2M | New |
| ISRG Intuitive Surgical Inc. | 1.45% | 37,896 | $19.8M | New |
| INSM Insmed Inc. | 1.30% | 256,281 | $17.7M | Reduce -10.5% |
| YMAB Y-Mabs Therapeutics Inc. | 1.26% | 2,194,278 | $17.2M | No change |
| SVRA Savara Inc. | 1.23% | 5,471,299 | $16.8M | Reduce -3.4% |
| JANX Janux Therapeutics Inc. | 0.99% | 253,262 | $13.6M | Add +53.7% |
| BIOA Bioage Labs Inc. | 0.98% | 2,304,901 | $13.3M | No change |
| INZY Inozyme Pharma Inc. | 0.87% | 4,280,308 | $11.9M | No change |
| LLY Eli Lilly & Co. | 0.81% | 14,364 | $11.1M | New |
| EWTX Edgewise Therapeutics Inc. | 0.79% | 402,773 | $10.8M | Add +4.7% |
| PHVS Pharvaris NV | 0.79% | 560,723 | $10.7M | Reduce -6.6% |
| AEROVATE THERAPEUTICS INC | 0.73% | 3,758,686 | $10.0M | No change |
| NARI Inari Medical Inc. | 0.68% | 180,456 | $9.2M | Add +99.8% |
| SNDX Syndax Pharmaceuticals Inc. | 0.64% | 658,627 | $8.7M | Reduce -16.3% |
| INBX Inhibrx Biosciences Inc. | 0.59% | 527,190 | $8.1M | Reduce -1.7% |
| IMNM Immunome Inc. | 0.58% | 746,824 | $7.9M | Add +10.3% |
| COGT Cogent Biosciences Inc. | 0.47% | 823,160 | $6.4M | Reduce -63.7% |
| ACHV Achieve Life Sciences Inc. | 0.34% | 1,306,482 | $4.6M | Reduce -13.7% |
| ERAS Erasca Inc. | 0.33% | 1,795,880 | $4.5M | Reduce -2.5% |
| ESTA Establishment Labs Holdings | 0.32% | 95,305 | $4.4M | Reduce -47.5% |
| AVTR Avantor Inc. | 0.31% | 200,000 | $4.2M | New |
| EW Edwards Lifesciences Corp. | 0.22% | 40,000 | $3.0M | Reduce -80.3% |
| EXAS Exact Sciences Corp. | 0.21% | 52,042 | $2.9M | Add +38.3% |
| IMTX Immatics NV | 0.18% | 343,206 | $2.4M | Reduce -11.1% |
| DHR Danaher Corp. | 0.17% | 10,000 | $2.3M | New |
| NXTC Nextcure Inc. | 0.15% | 2,671,856 | $2.1M | No change |
| ANAB Anaptysbio Inc. | 0.13% | 132,927 | $1.8M | New |
| KROS Keros Therapeutics Inc. | 0.11% | 95,375 | $1.5M | New |
| BOLT Bolt Biotherapeutics Inc. | 0.11% | 2,754,437 | $1.5M | No change |
| IRON Disc Medicine Inc. | 0.11% | 22,752 | $1.4M | Reduce -45.0% |
| BDX Becton Dickinson and Co. | 0.08% | 4,951 | $1.1M | Reduce -67.4% |
| VIR Vir Biotechnology Inc. | 0.06% | 114,131 | $838K | Reduce -11.7% |
| ICUI Icu Medical Inc. | 0.06% | 5,000 | $776K | New |
| ELVN Enliven Therapeutics Inc. | 0.06% | 34,025 | $766K | New |
| IKENA ONCOLOGY INC | 0.05% | 382,616 | $627K | No change |
| TVTX Travere Therapeutics Inc. | 0.04% | 32,616 | $568K | New |
| GPCR Structure Therapeutics Inc. | 0.04% | 20,892 | $567K | Reduce -46.1% |
| LUNG Pulmonx Corp. | 0.03% | 61,326 | $416K | Reduce -1.6% |
| RNAM Avidity Biosciences Inc. | 0.03% | 13,789 | $401K | Reduce -54.8% |
Options reported separately and not counted above: AXSM calls ($8.5M).
Portfolio Sells Q3 2024 → Q4 2024
| NVO Novo-Nordisk A/S-Spons ADR | Sold out | 0.00% | −7.16 |
| ELAN Elanco Animal Health Inc. | Sold out | 0.00% | −4.28 |
| IDYA Ideaya Biosciences Inc. | Reduce -38.9% | 2.01% | −2.58 |
| AZN Astrazeneca PLC-Spons ADR | Reduce -19.5% | 3.13% | −2.09 |
| COGT Cogent Biosciences Inc. | Reduce -63.7% | 0.47% | −1.56 |
| INCY Incyte Corp. | Reduce -26.6% | 2.65% | −1.26 |
| EW Edwards Lifesciences Corp. | Reduce -80.3% | 0.22% | −0.89 |
| GH Guardant Health Inc. | Sold out | 0.00% | −0.77 |
| RVMD Revolution Medicines Inc. | Sold out | 0.00% | −0.76 |
| SVRA Savara Inc. | Reduce -3.4% | 1.23% | −0.76 |
| TGTX TG Therapeutics Inc. | Sold out | 0.00% | −0.69 |
| MRNS Marinus Pharmaceuticals Inc. | Sold out | 0.00% | −0.64 |
| SNDX Syndax Pharmaceuticals Inc. | Reduce -16.3% | 0.64% | −0.62 |
| CABA Cabaletta Bio Inc. | Sold out | 0.00% | −0.60 |
| KURA Kura Oncology Inc. | Sold out | 0.00% | −0.48 |
| PAHC Phibro Animal Health Corp. Class A | Sold out | 0.00% | −0.44 |
| ILMN Illumina Inc. | Sold out | 0.00% | −0.44 |
| INSM Insmed Inc. | Reduce -10.5% | 1.30% | −0.43 |
| ESTA Establishment Labs Holdings | Reduce -47.5% | 0.32% | −0.33 |
| TMO Thermo Fisher Scientific Inc. | Sold out | 0.00% | −0.30 |
| ACHV Achieve Life Sciences Inc. | Reduce -13.7% | 0.34% | −0.26 |
| BDX Becton Dickinson and Co. | Reduce -67.4% | 0.08% | −0.22 |
| IMTX Immatics NV | Reduce -11.1% | 0.18% | −0.19 |
| CATX Perspective Therapeutics Inc. | Sold out | 0.00% | −0.13 |
| PHVS Pharvaris NV | Reduce -6.6% | 0.79% | −0.13 |
| INBX Inhibrx Biosciences Inc. | Reduce -1.7% | 0.59% | −0.10 |
| GPCR Structure Therapeutics Inc. | Reduce -46.1% | 0.04% | −0.10 |
| RNAM Avidity Biosciences Inc. | Reduce -54.8% | 0.03% | −0.09 |
| ERAS Erasca Inc. | Reduce -2.5% | 0.33% | −0.09 |
| ATXS Astria Therapeutics Inc. | Sold out | 0.00% | −0.08 |
| IRON Disc Medicine Inc. | Reduce -45.0% | 0.11% | −0.06 |
| VIR Vir Biotechnology Inc. | Reduce -11.7% | 0.06% | −0.02 |
| LUNG Pulmonx Corp. | Reduce -1.6% | 0.03% | −0.01 |
Portfolio Buys Q3 2024 → Q4 2024
| GILD Gilead Sciences Inc. | New | 5.24% | +5.24 |
| ABBV Abbvie Inc. | New | 4.68% | +4.68 |
| SRPT Sarepta Therapeutics Inc. | New | 3.82% | +3.82 |
| SYK Stryker Corp. | New | 3.06% | +3.06 |
| JAZZ Jazz Pharmaceuticals PLC | Add +167.4% | 4.55% | +2.81 |
| REPL Replimune Group Inc. | Add +6442.7% | 2.80% | +2.75 |
| ALNY Alnylam Pharmaceuticals Inc. | New | 1.90% | +1.90 |
| ALKS Alkermes PLC | New | 1.89% | +1.89 |
| DXCM Dexcom Inc. | New | 1.65% | +1.65 |
| GMED Globus Medical Inc. Class A | New | 1.48% | +1.48 |
| ISRG Intuitive Surgical Inc. | New | 1.45% | +1.45 |
| BSX Boston Scientific Corp. | Add +155.2% | 2.27% | +1.33 |
| LLY Eli Lilly & Co. | New | 0.81% | +0.81 |
| RYTM Rhythm Pharmaceuticals Inc. | Add +43.6% | 1.63% | +0.43 |
| JANX Janux Therapeutics Inc. | Add +53.7% | 0.99% | +0.37 |
| NARI Inari Medical Inc. | Add +99.8% | 0.68% | +0.37 |
| AVTR Avantor Inc. | New | 0.31% | +0.31 |
| AXSM Axsome Therapeutics Inc. | Add +29.6% | 3.05% | +0.22 |
| DHR Danaher Corp. | New | 0.17% | +0.17 |
| ANAB Anaptysbio Inc. | New | 0.13% | +0.13 |
| KROS Keros Therapeutics Inc. | New | 0.11% | +0.11 |
| ICUI Icu Medical Inc. | New | 0.06% | +0.06 |
| ELVN Enliven Therapeutics Inc. | New | 0.06% | +0.06 |
| SLNO Soleno Therapeutics Inc. | Add +29.1% | 2.49% | +0.04 |
| TVTX Travere Therapeutics Inc. | New | 0.04% | +0.04 |
| EXAS Exact Sciences Corp. | Add +38.3% | 0.21% | +0.00 |
| EWTX Edgewise Therapeutics Inc. | Add +4.7% | 0.79% | −0.06 |
| IMNM Immunome Inc. | Add +10.3% | 0.58% | −0.24 |
| DYN Dyne Therapeutics Inc. | Add +38.8% | 1.85% | −0.45 |
Options Activity Q3 2024 → Q4 2024
| NVS Novartis AG-Sponsored ADR | put | Sold out | 200,000 | $23.0Mbefore exit |
| SLNO Soleno Therapeutics Inc. | put | Sold out | 300,000 | $15.1Mbefore exit |
| AXSM Axsome Therapeutics Inc. | put | Sold out | 150,000 | $13.5Mbefore exit |
| AXSM Axsome Therapeutics Inc. | call | New | 100,000 | $8.5M |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
Notes & Other Activity Q3 2024 → Q4 2024
| IMTXW Immatics NV -CW | *W EXP 07/01/202 | Sold out | 366,568 | $852Kbefore exit |
Bonds, preferreds, convertibles and warrants; not part of the stock holdings or percentages above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 53 | $1.9B | NTRA, VERA, GMAB, JAZZ, RAPP |
| Q1 2026 | 61 | $2.0B | NTRA, BMY, JAZZ, VERA, UTHR |
| Q4 2025 | 60 | $2.3B | NTRA, JAZZ, AZN, VERA, BMY |
| Q3 2025 | 55 | $1.6B | NTRA, GILD, VERA, UTHR, JAZZ |
| Q2 2025 | 55 | $1.5B | NTRA, GILD, LLY, JAZZ, VERA |
| Q1 2025 | 59 | $1.3B | NTRA, SYK, VERA, JAZZ, MDT |
| Q4 2024 | 60 | $1.4B | NTRA, VERA, GILD, ABBV, JAZZ |
| Q3 2024 | 56 | $1.2B | NTRA, VERA, NVO, AZN, IDYA |
| Q2 2024 | 71 | $1.6B | NTRA, VERA, ASND, NVO, EW |
| Q1 2024Amended | 66 | $1.7B | NTRA, VERA, ASND, AEROVATE THERAPEUTICS INC, MRK |